Evolus (NASDAQ:EOLS) Earns “Buy” Rating from BTIG Research

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $13.00 price objective on the stock. BTIG Research’s target price points to a potential upside of 96.08% from the stock’s previous close.

Several other equities research analysts have also recently commented on the stock. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Trading Down 1.8%

Shares of NASDAQ EOLS opened at $6.63 on Wednesday. Evolus has a 1-year low of $3.86 and a 1-year high of $10.20. The company has a market cap of $436.62 million, a PE ratio of -9.90 and a beta of 1.34. The company has a 50-day moving average of $5.82 and a two-hundred day moving average of $5.55.

Evolus (NASDAQ:EOLS) last announced its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $73.14 million for the quarter, compared to the consensus estimate of $72.52 million. During the same period in the previous year, the company posted ($0.30) earnings per share. As a group, equities research analysts forecast that Evolus will post -0.38 earnings per share for the current year.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 13,669 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $4.75, for a total value of $64,927.75. Following the completion of the sale, the insider owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. This represents a 2.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.00% of the company’s stock.

Institutional Investors Weigh In On Evolus

Several large investors have recently bought and sold shares of EOLS. Larson Financial Group LLC increased its stake in Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Evolus in the fourth quarter valued at approximately $34,000. Wexford Capital LP bought a new stake in Evolus in the third quarter valued at approximately $37,000. Aquatic Capital Management LLC bought a new stake in Evolus in the third quarter valued at approximately $48,000. Finally, State of Wyoming bought a new stake in Evolus in the fourth quarter valued at approximately $63,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.